Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006223 · ClinicalTrials.gov registry record · Phase 3
flt3L in Treating Patients With Acute Myeloid Leukemia
A Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00006223: Completed Phase 3 study, sponsored by Eastern Cooperative Oncology Group.
NCT00006223 is a Phase 3 study that has completed, run by Eastern Cooperative Oncology Group. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006223, a Phase 3 study, has completed, sponsored by Eastern Cooperative Oncology Group.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Drugs such as flt3L may stimulate a person's immune system and help kill cancer cells. It is not yet known if flt3L is effective in treating acute myeloid leukemia. PURPOSE: Randomized phase III trial to determine the effectiveness of flt3L in treating patients who have acute myeloid leukemia that is in remission.
Interventions
- BIOLOGICAL recombinant flt3 ligand
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-07 |
| Est. Completion | 2007-01 |
| Phase | Phase 3 |
What the finished NCT00006223 record still lists
NCT00006223 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which recombinant flt3 ligand is the first listed.
NCT00006223 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00006223 about?
NCT00006223 is a clinical study titled "flt3L in Treating Patients With Acute Myeloid Leukemia". RATIONALE: Drugs such as flt3L may stimulate a person's immune system and help kill cancer cells. It is not yet known if flt3L is effective in treating acute myeloid leukemia. PURPOSE: Randomized phase III trial to determine the effectiveness of flt3L in treating patients who have acute myeloid leu...
What is the current status of trial NCT00006223?
This trial is currently completed. It is a Phase 3 study. The study started on 2000-07. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00006223?
The interventions under investigation include: recombinant flt3 ligand (BIOLOGICAL).
Who is sponsoring clinical trial NCT00006223?
This trial is sponsored by Eastern Cooperative Oncology Group, which has 141 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia